---
title: Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory
  multiple myeloma with renal impairment
date: '2023-09-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37731379/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230922181049&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: We evaluated patients with relapsed multiple myeloma with renal impairment
  (RI treated with standard of care ide-cel, as outcomes with CAR-T therapy are unknown
  in this population. RI was defined as creatinine clearance (CrCl < 50 ml/min. CrCl
  of < 30 ml/min or dialysis dependence were defined as severe RI. The study cohort
  included 214 patients, 28 (13% patients with RI, including 11 patients severe RI
  (dialysis, n=1. Patients with RI were older, more likely to be female and had ...
disable_comments: true
---
We evaluated patients with relapsed multiple myeloma with renal impairment (RI treated with standard of care ide-cel, as outcomes with CAR-T therapy are unknown in this population. RI was defined as creatinine clearance (CrCl < 50 ml/min. CrCl of < 30 ml/min or dialysis dependence were defined as severe RI. The study cohort included 214 patients, 28 (13% patients with RI, including 11 patients severe RI (dialysis, n=1. Patients with RI were older, more likely to be female and had ...